News · 26 weeks50+63%
2026-03-012026-08-23
Mix2490d
- SEC Filings7(29%)
- Analyst6(25%)
- Other4(17%)
- Insider4(17%)
- Earnings2(8%)
- Leadership1(4%)
Latest news
25 items- INSIDERChief Financial Officer Elston George acquired 5,000 shares, gifted 64,953 shares, received a gift of 64,953 shares and disposed of 5,000 shares, decreasing direct ownership by 65% to 32,517 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- INSIDERDirector Zaderej Karen L. bought $52,258 worth of shares (10,600 units at $4.93), increasing direct ownership by 28% to 49,100 units (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- ANALYSTEyePoint downgraded by Chardan Capital Markets with a new price targetChardan Capital Markets downgraded EyePoint from Buy to Neutral and set a new price target of $5.00
- ANALYSTEyePoint downgraded by RBC Capital Mkts with a new price targetRBC Capital Mkts downgraded EyePoint from Outperform to Sector Perform and set a new price target of $5.00
- ANALYSTEyePoint downgraded by H.C. WainwrightH.C. Wainwright downgraded EyePoint from Buy to Neutral
- ANALYSTEyePoint downgraded by Cantor FitzgeraldCantor Fitzgerald downgraded EyePoint from Overweight to Neutral
- SECEyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- PREyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD– DURAVYU was non-inferior to on-label aflibercept control (nominal p-value = 0.0096) in an ad hoc analysis excluding a 4% asymmetric cohort (9 of 211 patients) who experienced vision loss (≥ 15 letters) unrelated to wet AMD; primary endpoint not achieved in full dataset, confounded by this asymmetric cohort – – LUGANO demonstrated clinically meaningful results that reinforce DURAVYU’s potential to improve the treatment paradigm in wet AMD, with compelling key secondary endpoints, including reduction in treatment burden, supplement-free rates, favorable safety profile with redosing, and strong anatomic control through Week 56 compared to on-label aflibercept – – 42% reduction in treatment
- PREyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 14,600 shares of EyePoint common stock to two new employees. The stock options were granted on August 14, 2026. The grants were approved by the Compensation Committee and made as an inducement material
- SECSEC Form S-8 filed by EyePoint Inc.S-8 - EyePoint, Inc. (0001314102) (Filer)
- SECSEC Form 10-Q filed by EyePoint Inc.10-Q - EyePoint, Inc. (0001314102) (Filer)
- SECEyePoint Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- PREyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments– Topline data from LUGANO pivotal Phase 3 wet AMD clinical trial expected in August 2026 –– – Topline data from LUCIA pivotal Phase 3 wet AMD clinical trial anticipated in Q4 2026 –– – Pivotal Phase 3 DME clinical trials, COMO and CAPRI, fully enrolled over 480 patients in 5 months; topline data expected in Q4 2027 –– – $180 million of cash and investments as of June 30, 2026, with runway into Q4 2027 –– WATERTOWN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced financial results for the second quarter end
- SECEyePoint Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- PREyePoint Completes Enrollment of Both Pivotal Phase 3 Trials of DURAVYU™ for Treatment of Diabetic Macular Edema (DME)– COMO and CAPRI trials together rapidly enrolled over 480 participants in five months, demonstrating continued enthusiasm for DURAVYU trial participation among retinal specialists and patients –– – Topline 56-week data for both DME trials anticipated in 4Q 2027 – WATERTOWN, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced it has completed enrollment in COMO and CAPRI, the two global Phase 3 clinical trials of DURAVYU™ (vorolanib intravitreal insert) for the treatment of diabetic macular edema (DME). Over 480
- SECEyePoint Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- ANALYSTStifel initiated coverage on EyePoint with a new price targetStifel initiated coverage of EyePoint with a rating of Buy and set a new price target of $40.00
- PREyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., July 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 63,500 shares of EyePoint common stock to two new employees. The stock options were granted on July 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material
- INSIDERPresident and CEO Duker Jay S. converted options into 16,667 shares and covered exercise/tax liability with 8,059 shares, increasing direct ownership by 873% to 9,594 units (SEC Form 4) (for withholding tax)4 - EyePoint, Inc. (0001314102) (Issuer)
- PREyePoint Appoints Tarek S. Hassan, M.D., as Chief Strategic Science OfficerWATERTOWN, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing innovative therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of Tarek S. Hassan, M.D., as Senior Vice President, Chief Strategic Science Officer. Dr. Hassan will report directly to Jay S. Duker, M.D., President and CEO of EyePoint, and will serve as a member of the executive leadership team. A globally recognized retina specialist and key opinion leader with more than 35 years of experience, Dr. Hassan will provide strategic guidance across the Company’s portfolio to optimize development, potentia
- ANALYSTCantor Fitzgerald resumed coverage on EyePoint with a new price targetCantor Fitzgerald resumed coverage of EyePoint with a rating of Overweight and set a new price target of $47.00
- INSIDERChief Medical Officer Ribeiro Ramiro sold $73,167 worth of shares (4,875 units at $15.01) and exercised 4,875 shares at a strike of $8.26 (SEC Form 4)4 - EyePoint, Inc. (0001314102) (Issuer)
- SECEyePoint Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - EyePoint, Inc. (0001314102) (Filer)
- PREyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)WATERTOWN, Mass., June 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (NASDAQ:EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 39,700 shares of EyePoint common stock to three new employees. The stock options were granted on June 15, 2026. The grants were approved by the Compensation Committee and made as an inducement material
- INSIDERChief Financial Officer Elston George converted options into 7,500 shares and covered exercise/tax liability with 3,627 shares, increasing direct ownership by 4% to 91,691 units (SEC Form 4) (withholding obligation)4 - EyePoint, Inc. (0001314102) (Issuer)
EYPT FAQ
6 questionsWhat does EyePoint Inc. do?
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation...Where does EYPT stock trade?
EyePoint Inc. (EYPT) is listed on NASDAQ.What sector and industry is EYPT in?
EyePoint Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.What are analysts saying about EYPT?
EyePoint Inc. has had 8 recent analyst actions on file. The most recent action was from Chardan Capital Markets: Neutral with a $500.00 price target on 2026-08-18.What companies are similar to EYPT?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare EYPT side-by-side with any of them on Quantisnow.How can I track EYPT on Quantisnow?
Quantisnow aggregates EyePoint Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EYPT to receive live email and push alerts on every new disclosure.